C. auris: A New Global Health Threat
C. auris, a new Candida strain, has been identified by CDC and other health authorities as a serious public health threat as it is multi-drug resistant, has resulted in high mortality rates (~60%) and can be spread from patients (and surfaces) to other patients, resulting in hospital outbreaks. In the U.S., there have been a small, but rapidly growing number of patients with C. auris infections.
Ibrexafungerp for Multidrug-Resistant Candida auris
Ibrexafungerp (formerly SCY-078) has shown fungicidal activity against clinically relevant Candida species and potent in vitro activity against strains of Candida that are resistant to azoles and echinocandins. We have an ongoing open label study evaluating the safety and efficacy of ibrexafungerp for the treatment of C.auris infections.